A. STAR EXPERIMENTAL DRUG DEVELOPMENT CENTRE EDDC

Neither. It is a research and development center.

A*STAR Experimental Drug Development Centre (EDDC) is Singapore's national drug discovery and development platform. As a part of the Agency for Science, Technology and Research (A*STAR), EDDC plays a crucial role in translating cutting-edge scientific research into innovative drug candidates to address unmet medical needs.

EDDC's core mission is to bridge the gap between basic scientific discoveries and clinical application. It focuses on the entire spectrum of preclinical drug development, including target validation, hit identification, lead optimization, and IND (Investigational New Drug)-enabling studies. The center collaborates extensively with academic institutions, hospitals, and industry partners, both locally and internationally, to accelerate the development of new therapies across various disease areas, such as oncology, infectious diseases, and metabolic disorders.

EDDC operates as a research and development organization, leveraging state-of-the-art facilities and a multidisciplinary team of scientists to drive the creation of novel small molecules and biologics. Its ultimate goal is to deliver drug candidates that can progress into clinical trials, ultimately benefiting patients worldwide.

A. STAR EXPERIMENTAL DRUG DEVELOPMENT CENTRE (EDDC) is a drug discovery and development research institute. It does not typically manufacture or sell commercial therapeutic products directly to the market. Instead, its "products" are novel drug candidates and technologies in various stages of preclinical and early clinical development, which are often licensed to pharmaceutical companies for further development, manufacturing, and commercialization.

Their output includes:

Drug Candidates

Small molecule therapeutics targeting various diseases

Biologics such as antibodies and therapeutic proteins

Therapeutic Areas of Focus

Oncology (e.g., novel cancer therapies, targeted inhibitors)

Infectious Diseases (e.g., antivirals for dengue, COVID-19, other emerging pathogens)

Metabolic Diseases

Inflammatory Diseases

Research Tools and Technologies

Novel assay systems for drug screening

Biomarkers for disease diagnosis and treatment response monitoring

Intellectual Property

Patents covering novel chemical entities, therapeutic targets, and drug discovery processes

Licensing agreements for their drug candidates and technologies with industry partners

Examples of their advanced programs or licensed assets often include drug candidates that have progressed into clinical trials under partners.